Literature DB >> 10693996

Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants.

S C Buckingham1, A J Bush, J P Devincenzo.   

Abstract

OBJECTIVE: To evaluate the relationship between nasal quantity of respiratory syncytial virus (RSV) and disease severity in hospitalized infants without underlying cardiopulmonary disease or immunodeficiency.
METHODS: Nasal aspirates were obtained from hospitalized infants <24 months of age with recently identified RSV infection and evaluated for RSV quantity by a standard plaque assay on HEp-2 cell monolayers. Subjects were classified as having "severe" disease if they required mechanical ventilation at the time of sample collection and as having "nonsevere" disease if they did not. Linear modeling was used to determine the relationship between nasal RSV quantity and various independent variables, including disease severity.
RESULTS: Nasal aspirates from 39 patients were evaluated. Age, gender and mean duration of time from symptom onset to sample acquisition (5 days) were similar between the severe (n = 15) and nonsevere (n = 24) groups. Significantly more infants were born at <35 weeks gestation in the severe disease group (7 of 15 vs. 3 of 24, P = 0.017), and infants born at <35 weeks gestation were significantly more likely to be of non-Caucasian ethnicity than were infants born at > or =35 weeks gestation (8 of 10 vs. 12 of 29, P = 0.035). The linear model found that higher nasal RSV quantities were associated with severe disease [mean +/- SEM, 5.06 +/- 0.34 log plaque-forming units (pfu)/ml vs. 3.91 +/- 0.35 log pfu/ml, P = 0.022], gestational age > or =35 weeks (5.44 +/- 0.27 log pfu/ml vs. 3.52 +/- 0.45 log pfu/ml, P = 0.002) and non-Caucasian ethnicity (5.16 +/- 0.30 log pfu/ml vs. 3.80 +/- 0.37 log pfu/ml, P = 0.006).
CONCLUSIONS: Nasal RSV quantity correlates with disease severity in hospitalized infants with recently identified RSV infection.

Entities:  

Mesh:

Year:  2000        PMID: 10693996     DOI: 10.1097/00006454-200002000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  49 in total

1.  Human adenovirus species in children with acute respiratory illnesses.

Authors:  Varvara Probst; Emily K Datyner; Zaid Haddadin; Danielle A Rankin; Lubna Hamdan; Herdi K Rahman; Andrew Spieker; Laura S Stewart; Claudia Guevara; Erin Yepsen; Jonathan E Schmitz; Natasha B Halasa
Journal:  J Clin Virol       Date:  2020-12-11       Impact factor: 3.168

2.  Viral load drives disease in humans experimentally infected with respiratory syncytial virus.

Authors:  John P DeVincenzo; Tom Wilkinson; Akshay Vaishnaw; Jeff Cehelsky; Rachel Meyers; Saraswathy Nochur; Lisa Harrison; Patricia Meeking; Alex Mann; Elizabeth Moane; John Oxford; Rajat Pareek; Ryves Moore; Ed Walsh; Robert Studholme; Preston Dorsett; Rene Alvarez; Robert Lambkin-Williams
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

3.  Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection.

Authors:  Christy M Tabarani; Cynthia A Bonville; Manika Suryadevara; Patrick Branigan; Dongliang Wang; Danning Huang; Helene F Rosenberg; Joseph B Domachowske
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

4.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.

Authors:  John DeVincenzo; Robert Lambkin-Williams; Tom Wilkinson; Jeffrey Cehelsky; Sara Nochur; Edward Walsh; Rachel Meyers; Jared Gollob; Akshay Vaishnaw
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

6.  T-Cell Responses in Adults During Natural Respiratory Syncytial Virus Infection.

Authors:  D Roumanes; A R Falsey; S Quataert; S Secor-Socha; F E-H Lee; H Yang; S Bandyopadhyay; J Holden-Wiltse; D J Topham; E E Walsh
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

7.  Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology.

Authors:  H A Haeberle; W A Kuziel; H J Dieterich; A Casola; Z Gatalica; R P Garofalo
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Authors:  Monica E Brint; Joshua M Hughes; Aditya Shah; Chelsea R Miller; Lisa G Harrison; Elizabeth A Meals; Jacqueline Blanch; Charlotte R Thompson; Stephania A Cormier; John P DeVincenzo
Journal:  Pediatr Res       Date:  2017-08-09       Impact factor: 3.756

9.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

10.  Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults.

Authors:  Coley B Duncan; Edward E Walsh; Derick R Peterson; F Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.